Primary patency ( · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery
It is very uncertain whether PTFE changes primary patency (24 months) compared with PTFE with vein cuff (very low certainty).
2 findings from 1 review
OR 1.08 [0.58, 2.01]
Studies not reported
Very low
no estimate extracted
Studies not reported
No studies found
Secondary patency (24 months) · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery
It is very uncertain whether PTFE changes secondary patency (24 months) compared with PTFE with vein cuff (very low certainty).
1 finding from 1 review
OR 1.22 [0.67, 2.23]
Studies not reported
Very low
Limb salvage · people with peripheral vascular disease requiring below‐knee femoro‐popliteal bypass surgery
PTFE showed no clear difference in limb salvage (24 months) compared with PTFE with vein cuff (low certainty).
1 finding from 1 review
OR 1.34 [0.72, 2.49]
Studies not reported
Low
Primary patency ( · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE showed no clear difference in primary patency (24 months) compared with dacron (low certainty).
2 findings from 1 review
OR 1.23 [0.92, 1.65]
Studies not reported
Low
OR 1.67 [0.96, 2.9]
Studies not reported
Low
Secondary patency (24 months) · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE may leads to higher secondary patency (24 months) compared with dacron (low certainty).
1 finding from 1 review
OR 1.54 [1.04, 2.28]
Studies not reported
Low
Limb salvage · people with peripheral vascular disease requiring above‐knee femoro‐popliteal bypass surgery
PTFE showed no clear difference in limb salvage (24 months) compared with dacron (low certainty).
1 finding from 1 review
OR 0.82 [0.27, 2.48]
Studies not reported
Low
All‐cause mortality · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower all‐cause mortality compared with bare stents (low certainty).
1 finding from 1 review
Hepatic encephalopathy · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes hepatic encephalopathy compared with bare stents (very low certainty).
2 findings from 1 review
Kidney failure · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes kidney failure compared with bare stents (very low certainty).
1 finding from 1 review
Shunt dysfunctiona · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunctiona compared with bare stents (low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower upper gastrointestinal bleeding compared with bare stents (low certainty).
2 findings from 1 review
Recurrence of ascites · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower recurrence of ascites compared with bare stents (low certainty).
2 findings from 1 review
Shunt dysfunction · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
ePTFE‐covered stents may leads to lower shunt dysfunction compared with bare stents (low certainty).
1 finding from 1 review
Total mortalitya · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes all‐cause mortalitya compared with bare stents (very low certainty).
1 finding from 1 review
Procedure‐related complications · transjugular intrahepatic portosystemic shunt in people with liver cirrhosis
It is very uncertain whether ePTFE‐covered stents changes procedure‐related complications compared with bare stents (very low certainty).
1 finding from 1 review